Antimicrobial resistance to benzylpenicillin in invasive pneumococcal disease in Belgium, 2003-2010: the effect of altering clinical breakpoints

被引:14
作者
Goossens, M. C. [1 ]
Catry, B. [1 ]
Verhaegen, J. [2 ]
机构
[1] Healthcare Associated Infect & Antimicrobial Resi, Sci Inst Publ Hlth, B-1050 Brussels, Belgium
[2] Univ Hosp, Belgian Natl Reference Lab Pneumococci, Louvain, Belgium
关键词
Antibiotic resistance; clinical microbiology; Streptococcus pneumoniae (pneumococcus); surveillance system; STREPTOCOCCUS-PNEUMONIAE;
D O I
10.1017/S0950268812001057
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The Belgian data (2003-2010) for the European Antimicrobial Resistance Surveillance Network (EARS-Net) showed a significant decreasing trend in the proportion of penicillin non-susceptible Streptococcus pneumoniae (9.4% to <1%) from blood and CSF isolates. We found that 75% of this decrease was explained by a change in Clinical and Laboratory Standards Institute (CLSI) breakpoints as the trend disappeared if only the new breakpoints were applied. Applying only European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints also resulted in a relatively stable proportion of penicillin non-susceptibility (average 5%), but this proportion was 7-13 times higher than with the new CLSI breakpoints. When the new CLSI breakpoints alone are used, fewer than 1% of bacteraemia isolates were penicillin non-susceptible during the entire period, but the proportion of non-susceptible meningitis isolates rose from 6.3% in 2003 to 15.9% between 2003 and 2010. Changing breakpoints should lead to retrospective analysis of historical data to minimize wrongly interpreting resistance trends.
引用
收藏
页码:490 / 495
页数:6
相关论文
共 10 条
[1]  
Clinical and Laboratory Standards Institute [CLSI], 2005, M100S15 CLSI
[2]  
Drlica K, 2011, ANTIBIOTIC RESISTANC, P55
[3]  
European Centre for Disease Prevention and Control (ECDC), 2010, ANT RES SURV EUR 201
[5]   TESTING OF STREPTOCOCCUS-PNEUMONIAE FOR RESISTANCE TO PENICILLIN [J].
MARSHALL, KJ ;
MUSHER, DM ;
WATSON, D ;
MASON, EO .
JOURNAL OF CLINICAL MICROBIOLOGY, 1993, 31 (05) :1246-1250
[6]   Socioeconomic determinants of outpatient antibiotic use in Europe [J].
Masiero, Giuliano ;
Filippini, Massimo ;
Ferech, Matus ;
Goossens, Herman .
INTERNATIONAL JOURNAL OF PUBLIC HEALTH, 2010, 55 (05) :469-478
[7]   Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species [J].
Pletz, Mathias W. ;
Maus, Ulrich ;
Krug, Norbert ;
Welte, Tobias ;
Lode, Hartmut .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2008, 32 (03) :199-206
[8]  
Reingold A., 2008, Morbidity and Mortality Weekly Report, V57, P1353
[9]   Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral β-lactams [J].
Van Kerkhoven, D ;
Peetermans, WE ;
Verbist, L ;
Verhaegen, J .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (03) :691-696
[10]   Rationale for Revised Penicillin Susceptibility Breakpoints versus Streptococcus pneumoniae: Coping with Antimicrobial Susceptibility in an Era of Resistance [J].
Weinstein, Melvin P. ;
Klugman, Keith P. ;
Jones, Ronald N. .
CLINICAL INFECTIOUS DISEASES, 2009, 48 (11) :1596-1600